International Journal for Parasitology 50 (2020) 171–176

Contents lists available at ScienceDirect

International Journal for Parasitology

journal homepage: www.elsevier.com/locate/ijpara

Vaccination against canine leishmaniasis in Brazil

Filipe Dantas-Torres [a,*], Fábio dos Santos Nogueira [b], Ingrid Menz [c], Paulo Tabanez [d], Sydnei Magno da Silva [e], Vitor Márcio Ribeiro [f], Guadalupe Miró [g], Luís Cardoso [h], Christine Petersen [i], Gad Baneth [j], Gaetano Oliva [k], Laia Solano-Gallego [l], Lluís Ferrer [l], Maria Grazia Pennisi [m], Patrick Bourdeau [n], Carla Maia [o], Domenico Otranto [p], Luigi Gradoni [q], Orin Courtenay [r], Carlos Henrique Nery Costa [s]

[a] Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil
[b] Fundação Educacional de Andradina, Andradina, Brazil
[c] Self-employed Veterinarian, Campinas, Brazil
[d] Self-employed Veterinarian, Brasília, Brazil
[e] Department of Immunology, Microbiology and Parasitology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil
[f] Veterinary School, Pontifical Catholic University of Minas Gerais, Betim, Brazil
[g] Department of Animal Health, Veterinary Faculty, Universidad Complutense de Madrid, Madrid, Spain
[h] Department of Veterinary Sciences, and Animal and Veterinary Research Centre, University of Trás-os-Montes e Alto Douro (UTAD), Vila Real, Portugal
[i] Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, United States
[j] Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel
[k] Department of Veterinary Medicine and Food Production, University of Naples Federico II, Naples, Italy
[l] Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain
[m] Department of Veterinary Sciences, University of Messina, Polo Universitario Annunziata, Messina, Italy
[n] Veterinary School of Nantes ONIRIS, University of Nantes, LUNAM, Nantes, France
[o] Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), Lisbon, Portugal
[p] Department of Veterinary Medicine, University of Bari, Valenzano, Italy
[q] Unit of Vector-borne Diseases, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
[r] Zeeman Institute, and School of Life Sciences, University of Warwick, Coventry, United Kingdom
[s] Department of Community Medicine, Federal University of Piauí, Teresina, Brazil

ARTICLE INFO

Article history:
Received 16 August 2019
Received in revised form 29 December 2019
Accepted 2 January 2020
Available online 29 February 2020

Keywords:
Leishmania
Zoonosis
Prevention
Vaccination
Topical insecticides

ABSTRACT

Prevention of canine *Leishmania infantum* infection is critical to management of visceral leishmaniasis in people living in endemic areas of Brazil. A bill (PL 1738/11), currently under consideration, proposes to establish a national vaccination policy against canine leishmaniasis in Brazil. However, there is no solid scientific evidence supporting the idea that this could reduce transmission from infected vaccinated dogs to sand flies to a level that would significantly reduce the risk of *L. infantum* infection or visceral leishmaniasis in humans. Thus, we advocate that insecticide-impregnated collars should the first line protective measure for public health purposes and that vaccines are applied on a case-by-case, optional basis for individual dog protection.

1. Introduction

Brazil is one of the largest foci of human visceral leishmaniasis (VL) caused by *Leishmania infantum*, with an annual incidence ranging from 3455 to 4456 cases during 2013–2017 (Ministério da Saúde, 2019. Leishmaniose visceral - casos confirmados notificados no Sistema de Informação de Agravos de Notificação. Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinannet/leishvi/bases/leishvbrnet.def [accessed 10 June 2019]). Dogs have been serologically screened and culled as part of the national VL control programme, which also includes indoor residual spraying of insecticides and human VL treatment (Ministério da Saúde, 2014. Manual de vigilância e controle da leishmaniose visceral. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_controle_leishmaniose_visceral_1edicao.pdf [accessed 1 May 2019]). However, this strategy has not apparently led to reductions in either the incidence of human VL, or the infection prevalence in dogs, although statistically powered trials to test these intervention

* Corresponding author at: Av. Prof. Moraes Rego s/n, 50740465 Recife, Pernambuco, Brazil.
E-mail address: filipe.dantas@cpqam.fiocruz.br (F. Dantas-Torres).

https://doi.org/10.1016/j.ijpara.2020.01.001
0020-7519/

measures are generally lacking (Romero and Boelaert, 2010; Rocha et al., 2018).

Tools to prevent *L. infantum* infection or canine leishmaniasis (CanL) in dogs have been licensed in Brazil, including topical spot-on insecticides and insecticide-impregnated collars, and vaccines. Public reaction to culling pet dogs has also catalysed recent legislation to now allow veterinarians to treat infected seropositive dogs with miltefosine as an alternative to euthanasia (Ministério da Agricultura, Pecuária e Abastecimento, Ministério da Saúde, 2016. Nota Técnica N° 11/2016/CPV/DFIP/SDA/GM/MAPA. Available from: http://www.agricultura.gov.br/assuntos/insumos-agropecuarios/insumos-pecuarios/produtos-veterinarios/legislacao-1/notas-tecnicas/nota-tecnica-no-11–2016-cpv-dfip-sda-gm-mapa-de-1–09-2016.pdf/view [accessed 6 May 2019]).

In pursuit of an effective method to reduce VL transmission, a bill (PL 1738/11) to introduce obligatory annual canine vaccination is currently under Brazilian government-level examination (Câmera dos Deputados, 2019. PL 1738/2011. Available from: https://www.camara.leg.br/proposicoesWeb/fichadetramitacao?idProposicao=510841 [accessed 10 July 2019]). According to the bill, vaccination will be mandatory in areas of moderate (annual average of ≥2.4 to 4.4 human VL cases in the past 5 years) and intense (≥4.4 human VL cases per year) transmission, but not in areas of sporadic transmission (≥0.1 to <2.4 human VL cases per year), in line with previous classification of the Ministry of Health of Brazil (Ministério da Saúde, 2014. Manual de vigilância e controle da leishmaniose visceral. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_controle_leishmaniose_visceral_1edicao.pdf [accessed 1 May 2019]).

Originally proposed in 2011 to prevent CanL, the bill was accepted in 2018 by the Committee on Social Security and Family and by the Committee on Agriculture, Livestock, Supply and Rural Development. It is now under analysis by the Committee on Finance and Taxation (as of 17 February 2020). If accepted, the bill will be assessed for constitutional, legal, juridical and legislative regulations by the Committee on Constitution, Justice and Citizenship, and scrutinised by the plenary of the Chamber of Deputies, and/or voted on by the Brazilian Federal Senate.

With such an important decision on the national VL control policy being imminent, the aim of this paper is to provide a review of the scientific evidence supporting the proposed vaccination strategy in light of alternative intervention methods, and in so doing to provide the authors' informed expert opinion on the bill PL 1738/11.

2. Licensed CanL vaccines

The vaccine Leishmune® (Zoetis), was licensed in 2003, but the requirements for research, development, production, evaluation, registration, license renewal, commercialization, and use of CanL vaccines were amended in 2007 (Ministério da Agricultura, Pecuária e Abastecimento, Ministério da Saúde, 2007. Instrução Normativa Interministerial M31/2007. Available from: http://sistemasweb.agricultura.gov.br/sislegis/action/detalhaAto.do%3Fmethod=visualizarAtoPortalMapa%26chave=815005048 [accessed 6 May 2019]), and this vaccine was withdrawn from the market in 2014. According to a technical note of the Ministry of Agriculture, Livestock and Food Supply, Leishmune® did not completely satisfy the requirements for phase III studies (Ministério da Agricultura, Pecuária e Abastecimento, 2014. Nota Técnica N° 038/2014/DFIP/SDA. Available from: http://www.agricultura.gov.br/assuntos/insumos-agropecuarios/insumos-pecuarios/produtos-veterinarios/arquivos-comunicacoes-e-instrucoes-tecnicas/nota-tecnica-dfip-38–14-leishmune.pdf [accessed 6 May 2019]). Another vaccine, Leish-Tec® (Ceva Animal Health), was licensed in 2007 and currently is the only CanL vaccine commercially available in Brazil.

An effective CanL vaccine should induce a strong and long-lasting proinflammatory (Th1-dominated) immune response in dogs in order to either (i) prevent the establishment of an initial infection, or (ii) control its progression towards severe disease and (iii) promote the abrogation of *Leishmania* transmissibility by vaccinated dogs if they become infected (Gradoni, 2015).

The best-case scenario (i) is difficult to achieve with current anti-protozoan vaccines, despite there being evidence from the field that in endemic areas a proportion of dogs, repeatedly exposed to sand flies potentially infected by *L. infantum*, never manifest evidence of infection (i.e. parasite demonstration by microscopy/culture or DNA amplification from target tissues), while presenting low antibody titres. The strong refractoriness to infection of these "resistant" dogs might be the result of a particular immunogenetic background (Soutter et al., 2019) or of natural booster doses determined by events of defective *L. infantum* transmission by the vector, as recently seen in a hamster-sand fly laboratory model (Gradoni, L., Bongiorno, G., Foglia Manzillo, V., Gizzarelli, M., Oliva, G., 2019. A hamster model of defective sand-fly transmission may explain the occurrence of canine *Leishmania* seroreactors without evidence of infection in endemic areas of visceral leishmaniasis. In: Proceedings of the 10th International Symposium on Phlebotomine Sandflies, ISOPS-10, 15–19 July 2019, Galàpagos, Ecuador).

As for scenario (ii), an effective vaccine could represent an important tool for veterinary care at the individual level for dogs exposed to the risk of *L. infantum* infection. A vaccine-mediated Th1-type immune response will impair parasite multiplication and dissemination. Increased parasite burden and dissemination are associated with pathologic immunoglobulin production and immune complex formation in dogs.

On the other hand, scenario (iii), theoretically associated with very good clinical efficacy of the vaccine, is of key importance as a public health intervention outcome. Dogs are the most important source of *L. infantum* infection to sand fly vectors (Quinnell and Courtenay, 2009). Canine infectiousness, which can only be ascertained by xenodiagnosis using colonised sand flies, is generally believed to be correlated with disease progression (Courtenay et al., 2002, 2014), although subclinically infected dogs (elsewhere defined as "asymptomatic") were shown to exhibit various degrees of infectiousness. Unfortunately, CanL studies suffer from a lack of consistency in the definition of subclinical dogs, which may have lead to contradictory conclusions (Dantas-Torres et al., 2014).

Table 1 summarises the main features of available CanL vaccines, by focusing on the above scenarios. Leish-Tec® is currently the only vaccine available in Brazil. The other two vaccines are commercially available in Europe, CaniLeish® (Virbac Animal Health) and LetiFend® (Laboratorios LETI) being licensed by the European Medicine Agency in 2011 and 2017, respectively. Importantly, these vaccines have not been tested for efficacy or effectiveness against human VL.

3. Can currently licensed CanL vaccines reduce the risk of infection or VL in humans?

A study on CaniLeish® revealed that significantly fewer of the sand flies which fed on the vaccinated dogs were infected compared with those which fed on the control dogs (Bongiorno et al., 2013). A previous study conducted in Brazil reported low transmission rates to sand flies among dogs vaccinated with either Leishmune® or Leish-Tec® (Fernandes et al., 2014), but a more recent study showed no statistically significant difference in the general comparison between Leish-Tec®-vaccinated and placebo dogs

Table 1
Main features of commercially available canine *Leishmania* vaccines.

Vaccine's features	Leish-Tec®	CaniLeish®	LetiFend®
Composition	Recombinant A2 protein adjuvanted with saponin	Purified excreted-secreted proteins from cultured *Leishmania infantum* adjuvanted with QA-21 saponin	Recombinant chimeric protein Q without adjuvant
Induces strong and long-lasting Th1-dominated immunity	Uncertain (only determined over 7 months post-vaccination)	Yes (determined over 12 months post-vaccination)	No (recently re-evaluated data did not detect significant stimulation of cellular responses)
Prevents the establishment of an initial infection	Partially (37% protection determined by seroconversion at 18 months sharply declining at 24 months post-vaccination; 55% protection determined by parasitological methods including xenodiagnosis)	No (*Leishmania* PCR-positive rates similar in vaccinated and control dogs)	Partially? (non-significant reduction in protection as determined by parasitological methods)
Controls infection progression towards disease	No (more than two-fold higher risk of developing disease at 24 months post-vaccination)	Partially (68% clinical protection at 24 months post-vaccination)	Partially (64% clinical protection at 24 months post-vaccination)
Promotes the abrogation of *Leishmania* transmissibility	Partially (40% reduction in transmissibility)	Partially (no reduction in transmissibility capacity, only reduction in infectivity rate and parasite load in sand flies)	Not tested for this feature
References	Regina-Silva et al. (2016) and Grimaldi et al. (2017)	Bongiorno et al. (2013), Moreno et al. (2014), Oliva et al. (2014)	Cotrina et al. (2018)

(Regina-Silva et al., 2016). Vaccination does partially protect dogs against development of severe clinical signs (Gradoni, 2015), which are correlated with infectiousness to sand flies (Courtenay et al., 2014) and therefore could have some impact on population-level transmission, but theoretically only if dogs disproportionately contributing to onward transmission are identified and vaccinated.

Mathematical models have suggested that canine vaccination could have limited to no effect on the infection incidence in humans compared with insecticide-impregnated collars (Sevá et al., 2016; Shimozako et al., 2017; Gomez et al., 2018). Other simulation studies assessed possible additive effects of Leishmune® or Leish-Tec® vaccination to dog culling in controlling human VL, the former based on data from Araçatuba (São Paulo) and Belo Horizonte (Minas Gerais), south-eastern Brazil (Palatnik-de-Sousa et al., 2009). While this study concluded that Leishmune® vaccination could increase the efficacy of culling against human VL incidence (Palatnik-de-Sousa et al., 2009), the Leish-Tec® study suggested that it probably would not have any additional impact on dog infection rates to protect humans in high-risk areas (Grimaldi et al., 2017).

In summary, there is no current scientific evidence that canine vaccination significantly reduces the infectiousness of infected vaccinated dogs. In addition, although there are no robustly designed community-level field studies to evaluate canine vaccination efficacy or effectiveness against human infection or VL disease incidence (Romero and Boelaert, 2010), the existing data suggest that current CanL vaccines need improvement to warrant a national canine vaccination policy as a public health intervention.

4. Can insecticide-impregnated collars protect dogs from *L. infantum* infection and reduce the risk of human infection and VL?

Three brands of insecticide-impregnated collars to protect dogs against sand fly bites are available in Brazil, Scalibor® ProtectorBand (MSD Animal Health), and Leevre® (Ourofino Animal Health), both of which contain 4% deltamethrin, and Seresto® (Bayer Animal Health), which contains 10% imidacloprid and 4.5% flumethrin. The collars are designed to reduce the number of sand flies feeding on treated animals and to increase sand fly mortality (Lucientes, J., 1999. Laboratory observations on the protection of dogs from the bites of *Phlebotomus perniciosus* with Scalibor® Protectorbands: preliminary results. In: Killick-Kendrick, R., ed. Canine leishmaniasis: an update. Proceedings of the International Canine Leishmaniasis Forum, ICLF, 28–31 January 1999, Barcelona, Spain; Halbig et al., 2000; David et al., 2001; Alves et al., 2015). Considering that the extrinsic incubation period of *L. infantum* in the vector is 5–7 days to reach the infectious form, these effects reduce the likelihood of a collared dog acquiring infection and being a source of *Leishmania* parasites for onward transmission. In this way collars are expected to reduce the number of infectious bites on humans.

Both Scalibor® and Seresto® are efficacious in reducing the incidence of infections in individual dogs, evidenced by reductions in seroconversion, detection of parasite DNA, parasite culture or cytology. From the 10 studies of variable design, Scalibor® provides a median 53.5% (interquartile range (IQR): 49.1%–80.4%; range: 42.4%–100%) protection against canine seroconversion incidence as tested across endemic regions including Brazil (Oliveira-Lima, J.W., Nonato de Souza, R., Teixeira, M.J., Pompeu, M., Killick-Kendrick, R., David, J.R., 2002. Preliminary results of a field trial to evaluate deltamethrin-impregnated collars for the control of canine leishmaniasis in northeast Brazil. In: Killick-Kendrick, R., ed. Canine leishmaniasis: moving towards a solution. Proceedings of the Second International Canine Leishmaniasis Forum, ICLF-2, 6–9 February, Seville, Spain; Camargo-Neves et al., 2004; Coura-Vital et al., 2018; Kazimoto et al., 2018; Lopes et al., 2018), North Africa (Aoun et al., 2008), and the Middle East (Gavgani et al., 2002). Of these, the five Brazilian studies report a median 48.3% (IQR: 48.0–53.0%; range: 42.4–69.7%) protective effect against *L. infantum* infection in dogs. In one follow-up study of 3742 seronegative Brazilian dogs, the efficacy of these collars against infection was 48%, estimated by intention-to-treat analysis that included all recruited dogs, irrespective of collar losses and other non-protocol events (Coura-Vital et al., 2018). The equivalent efficacy estimate by per-protocol analysis which included only dogs wearing collars continuously and adhering to the study protocol, increased to 63% (Coura-Vital et al., 2018).

Seresto®, tested less extensively, and exclusively in Italian sheltered dogs, provided a median level of protection of 93.4% (IQR: 90.9–96.7%; range: 88.3–100%) (Otranto et al., 2013; Brianti et al., 2014, 2016), which is relatively higher than Scalibor®, as substantiated by one comparative study of the two collars randomised between dogs. That study showed Seresto® prevented 88.3% of incidental canine infections compared with 61.8% by Scalibor® (Brianti et al., 2016). Moreover, Seresto® provided 8 months of

protection against sand flies, whereas Scalibor® is labelled for 4 months in Brazil and 5–6 months in Europe, although a recent laboratory study demonstrated a sustained anti-feeding efficacy of ≥94% for 12 months against *Phlebotomus perniciosus* (Paulin et al., 2018). As a consequence of this study, the Ministry of Health of Italy authorised the extension of the label recommendation of Scalibor® to 12 months (Ministero della Salute, 2018. Modifica dell'autorizzazione all'immissione in commercio del medicinale per uso veterinario «Scalibor Protectorband 48 cm e 65 cm collare antiparassitario per cani. Available from: https://www.gazzettaufficiale.it/eli/gu/2018/11/17/268/sg/pdf [accessed 12 June 2019]). This extended recommendation is also valid in other European countries such as Portugal and Spain (MSD Animal Health, 2019a. O que é a Scalibor? Available from: http://www.scalibor.pt/scalibor/qu-est-ce-que-scalibor [accessed 29 December 2019]; MSD Animal Health, 2019b. Scalibor® 12 meses. Available from: https://www.scalibor.es/collar-scalibor/scalibor-durante-12-meses-flebotomo [accessed 29 December 2019]).

From the public health perspective, only two studies have evaluated the protective effect of the community-wide deployment of Scalibor® dog collars on the incidence of *L. infantum* infection and clinical VL cases in humans, in this case children who are the high-risk group. Both studies were cluster randomised trial designs involving community-wide distribution of Scalibor® in hyperendemic villages in northwest Iran. In the first study, the authors estimated that the odds of seroconversion was reduced by 43% (95% confidence limits (CL): 10%, 63%) in ≤10-year-old children (the high risk group), and by 54% (95% CL: 30%, 70%) in dogs (Gavgani et al., 2002). The second study was an effectiveness trial against clinical VL in the same infant age group conducted in 80 randomly assigned villages, where collars were fitted to dogs prior to four consecutive transmission seasons. That trial was designed by researchers but implemented by the local Ministry of Health. At the end of the follow-up period, the relative risk of infantile VL was 50% (95% CL: 30%, 82%), with a 48% reduction in the absolute number of clinical infantile VL cases (Courtenay et al., 2019).

In addition to the epidemiological outcomes in dogs and humans, Scalibor® also has been reported to reduce domestic sand fly vector densities (Silva et al., 2018), and sand fly infection prevalence with *L. infantum* (Kazimoto et al., 2018); both studies were conducted in Brazil.

We found no peer-reviewed scientific publication on the efficacy of Leevre® in the international literature. According to a study report available online (Ourofino, 2000. Avaliação da eficácia da coleira LEEVRE, no controle do flebotomíneos *Lutzomyia longipalpis*, em condições experimentais, em cães. Available from: https://s3-sa-east-1.amazonaws.com/vetsmart-contents/Documents/DC/Ourofino/Relatorio_Estudo_Avaliacao_Leevre_Flebotomineos_Caes.pdf [accessed 6 May 2019]), this collar works for 6 months, with repellent efficacy against *Lutzomyia longipalpis*, ranging from 81% to 93%, and insecticidal efficacy ranging from 71 to 100%.

4.1. Intervention objectives

The majority of the collar studies achieved the reported levels of protection within 1–2 transmission seasons, or years, of intervention. However, it is important to recognise that most studies have collared and monitored outcomes in individual dogs, representing the degree of protection to be expected by pet owners purchasing and fitting collars to their owned dogs (e.g. household level protection). For public health objectives, by contrast, community-wide collar coverage is required so that the remaining population benefits from the consequential reductions in transmission (i.e. analogous to providing herd immunity by community vaccination). One key knowledge gap is the minimum coverage threshold (percent of total dogs collared) required in any given transmission intensity setting. For example, in the effectiveness trial in Iran, the mean annual Scalibor® coverage per village was 87% (95% CL: 84.2%, 89.0%, range: 65.7–100%), however changes in human VL incidence attributed to the intervention did not prove to relate to collar coverage, or indeed any other demographic measure in the studied villages (Courtenay et al., 2019). Moreover, field studies generally indicate that collars have been more efficacious in areas where transmission is seasonal (e.g. Italy), compared with areas where the transmission occurs all year round (e.g. Brazil) (Otranto and Dantas-Torres, 2013).

5. Summary guidelines for preventing *L. infantum* infection in dogs

The LeishVet association has published guidelines for the management of CanL (Solano-Gallego et al., 2011; Miró et al., 2017), with recommendations to help the veterinary clinician to better understand, diagnose, treat and prevent infection and disease. LeishVet has been involved in many meetings and discussions on this topic with veterinarians, human medical professionals, public health regulators from endemic and non-endemic countries, the pharmaceutical industry and organisations concerned with the hazard of zoonotic VL. The Brasileish group has also been involved in the organisation of scientific meetings and guidelines for the management of CanL in Latin America. Moreover, members of this group have been involved in advisory meetings on CanL and human VL, organised by public health authorities, including the Pan American Health Organisation and the Ministry of Health of Brazil. In the following lines, some major points from the LeishVet and Brasileish guidelines for preventing *L. infantum* infection in dogs are summarised:

- The main way to avoid *L. infantum* infection is to use topically applied pyrethroids (i.e. permethrin, deltamethrin or flumethrin) with proven activity against female sand flies. These products are available in spot-on formulations or in collars and reduce the risk of new infections in non-infected dogs and the biting of sand flies on already infected dogs.
- Currently available vaccines do not prevent the establishment of infection and may allow maintenance of an infected but clinically healthy status in some dogs. The decision to vaccinate should be based upon individual benefit/risk to the dog, age, breed, life-style or use, habitat, reproductive status, and owner compliance.
- Immune modulators assessed to date in CanL include domperidone and some dietary nucleotides in combination with an active hexose correlated compound. Domperidone has proven preventative efficacy and dietary nucleotides have been suggested to reduce disease progression in *L. infantum*-infected dogs, but more studies are needed to evaluate the real efficacy of both drugs. In particular, it is important to assess whether infected dogs treated with these immune modulators may serve as a source of *L. infantum* to sand flies (Travi and Miró, 2018).
- Other measures to prevent sand fly bites include: keeping dogs indoors from dusk to dawn; reducing microhabitats favourable to sand fly breeding in the vicinity of the house and in other locations where dogs spend time; and indoor house-spraying with residual insecticides.

6. Concluding remarks

Controlling CanL in Brazil is not an easy enterprise, owing to the inherent complexities involved in its transmission cycles in urban and rural settings. For decades, the public health authorities have attempted to reduce the incidence of VL through the mass

elimination of seropositive dogs, with no apparent success. The available scientific data support the community-wide use of insecticide-impregnated collars, rather than vaccination, to reduce the risk of infection in dogs and humans (Gavgani et al., 2002; Otranto et al., 2013; Brianti et al., 2014, 2016; Paulin et al., 2018; Courtenay et al., 2019). This conclusion is supported by others (EFSA Panel on Animal Health and Welfare, 2015). In 2015, the European Commission requested the scientific opinion of the European Food Safety Authority about CanL, with the objective of mitigating the probability of introduction of the infection into free areas in the European Union through movements of infected dogs. The Animal Health and Welfare Panel conducted systematic reviews to evaluate the efficacy of vaccines, topically applied insecticides and prophylactic medication. The panel members together with members of a working group on CanL (which includes some of the co-authors of the present paper: G. Baneth, P. Bourdeau, L. Gradoni and L. Solano-Gallego) concluded that topically applied insecticides were the most effective mitigation measure to reduce the probability of introduction and establishment of CanL in infection-free areas (EFSA Panel on Animal Health and Welfare, 2015).

The global expense of vaccination (i.e. three initial doses plus an annual booster vaccination, cold chain, and a range of consumables) and chemotherapeutic treatments are much higher than applying insecticide-impregnated collars (e.g. two collars per year for a collar labelled for 6 months of protection). Currently available CanL vaccines are recommended for use only in seronegative and healthy dogs. So, the costs of pre-testing add to the cost of vaccination. By contrast, the dog's infection and health status has little, if any, influence on the efficacy of insecticide-impregnated collars.

CanL disproportionately affects dogs living in low income areas in Brazil, as happens in most endemic foci in Latin America. Consequently, many dog owners living in the most affected areas cannot cover the costs of preventive measures. Hence, public health authorities in Brazil play a pivotal role in delivering health education for dog owners and promoting tangible actions that could help prevent *L. infantum* infection in dogs. Furthermore, even if privately owned dogs are protected, stray dogs will keep playing a role as reservoirs of *L. infantum* and thus a critical role in control campaigns.

In conclusion, we agree generally with the actions proposed by the bill 1738/11, but we strongly suggest replacing the mandatory vaccination of dogs with the community-wide application of insecticide-impregnated collars. While available vaccines can be recommended on a case-by-case basis, those should not replace the use of insecticide-impregnated collars because infected vaccinated dogs may still serve as a source of infection to the vectors, which may potentially transmit the parasites to naïve hosts.

Acknowledgements

FDT is the recipient of a research fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq; 313118/2018-3). CM has the support of the Portuguese Ministry of Education and Science (via Fundação para a Ciência e a Tecnologia, I.P.), through an Investigator Starting Grant (IF/01302/2015).

References

Alves, F.S., Oliveira, R.D., Aguiar, G.R., Moura, A.C.J., Leme, F.O.P., Araujo, R.B., Costa-Val, A.P., 2015. Antifeeding and short-term insecticidal effects against *Lutzomya longipalpis* in dogs treated with permethrin or deltamethrin. Rev. Bras. Ci. Vet. 22, 71–76.

Aoun, K., Chouihi, E., Boufaden, I., Mahmoud, R., Bouratbine, A., Bedoui, K., 2008. Efficacy of deltamethrin-impregnated collars Scalibor in the prevention of canine leishmaniasis in the area of Tunis. Arch. Inst. Pasteur Tunis. 85, 63–68.

Bongiorno, G., Paparcone, R., Foglia Manzillo, V., Oliva, G., Cuisinier, A.M., Gradoni, L., 2013. Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in *Phlebotomus perniciosus* fed on *Leishmania infantum* infected dogs - a preliminary xenodiagnosis study. Vet. Parasitol. 197, 691–695.

Brianti, E., Gaglio, G., Napoli, E., Falsone, L., Prudente, C., Solari Basano, F., Latrofa, M. S., Tarallo, V.D., Dantas-Torres, F., Capelli, G., Stanneck, D., Giannetto, S., Otranto, D., 2014. Efficacy of a slow-release imidacloprid (10%)/flumethrin (4.5%) collar for the prevention of canine leishmaniosis. Parasit. Vectors 7, 327.

Brianti, E., Napoli, E., Gaglio, G., Falsone, L., Giannetto, S., Solari Basano, F., Nazzari, R., Latrofa, M.S., Annoscia, G., Tarallo, V.D., Stanneck, D., Dantas-Torres, F., Otranto, D., 2016. Field evaluation of two different treatment approaches and their ability to control fleas and prevent canine leishmaniosis in a highly endemic area. PLoS Negl. Trop. Dis. 10, e0004987.

Camargo-Neves, V., Rodas, L.A.C., Pauliquévis Jr., C., 2004. Avaliação da efetividade da utilização de coleiras impregnadas com deltametrina a 4% para o controle da leishmaniose visceral americana no estado de Sao Paulo: resultados preliminares. BEPA 1, 7–14.

Cotrina, J.F., Iniesta, V., Monroy, I., Baz, V., Hugnet, C., Marañon, F., Fabra, M., Gómez-Nieto, L.C., Alonso, C., 2018. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis. Vaccine 36, 1972–1982.

Coura-Vital, W., Leal, G.G.A., Marques, L.A., Pinheiro, A.D.C., Carneiro, M., Reis, A.B., 2018. Effectiveness of deltamethrin-impregnated dog collars on the incidence of canine infection by *Leishmania infantum*: a large scale intervention study in an endemic area in Brazil. PLoS One. 13, e0208613.

Courtenay, O., Bazmani, A., Parvizi, P., Ready, P.D., Cameron, M.M., 2019. Insecticide-impregnated dog collars reduce infantile clinical visceral leishmaniasis under operational conditions in NW Iran: a community-wide cluster randomised trial. PLoS Negl. Trop. Dis. 13, e0007193.

Courtenay, O., Carson, C., Calvo-Bado, L., Garcez, L.M., Quinnell, R.J., 2014. Heterogeneities in *Leishmania infantum* infection: using skin parasite burdens to identify highly infectious dogs. PLoS Negl. Trop. Dis. 8, e2583.

Courtenay, O., Quinnell, R.J., Garcez, L.M., Shaw, J.J., Dye, C., 2002. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J. Infect. Dis. 186, 1314–1320.

Dantas-Torres, F., Baneth, G., Miró, G., Cardoso, L., Oliva, G., Solano-Gallego, L., Bourdeau, P., Otranto, D., 2014. Further thoughts on "Asymptomatic dogs are highly competent to transmit *Leishmania* (*Leishmania*) *infantum chagasi* to the natural vector". Vet. Parasitol. 204, 443–444.

David, J.R., Stamm, L.M., Bezerra, H.S., Souza, R.N., Killick-Kendrick, R., Lima, J.W., 2001. Deltamethrin-impregnated dog collars have a potent anti-feeding and insecticidal effect on *Lutzomyia longipalpis* and *Lutzomyia migonei*. Mem. Inst. Oswaldo Cruz 96, 839–847.

EFSA Panel on Animal Health and Welfare, 2015. Scientific opinion on canine leishmaniosis. EFSA J. 13, 4075.

Fernandes, C.B., Junior, J.T., de Jesus, C., Souza, B.M., Larangeira, D.F., Fraga, D.B., Tavares Veras, P.S., Barrouin-Melo, S.M., 2014. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis. Vaccine 32, 1287–1295.

Gavgani, A.S., Hodjati, M.H., Mohite, H., Davies, C.R., 2002. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360, 374–379.

Gomez, S.A., Chapman, L.A.C., Dilger, E., Courtenay, O., Picado, A., 2018. Estimating the efficacy of community-wide use of systemic insecticides in dogs to control zoonotic visceral leishmaniasis: a modelling study in a Brazilian scenario. PLoS Negl. Trop. Dis. 12, e0006797.

Gradoni, L., 2015. Canine *Leishmania* vaccines: still a long way to go. Vet. Parasitol. 208, 94–100.

Grimaldi Jr, G., Teva, A., Santos, C.B., Santos, F.N., Pinto, I.D., Fux, B., Leite, G.R., Falqueto, A., 2017. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by *Leishmania infantum* in an endemic area with high transmission rates. PLoS One 12, e0185438.

Halbig, P., Hodjati, M.H., Mazloumi-Gavgani, A.S., Mohite, H., Davies, C.R., 2000. Further evidence that deltamethrin-impregnated collars protect domestic dogs from sandfly bites. Med. Vet. Entomol. 14, 223–226.

Kazimoto, T.A., Amora, S.S.A., Figueiredo, F.B., Magalhães, J.M.E., Freitas, Y.B.N., Sousa, M.L.R., Melo, A.E.C.S., Campos, M.P., Alves, N.D., Werneck, G.L., 2018. Impact of 4% deltamethrin-impregnated dog collars on the prevalence and incidence of canine visceral leishmaniasis. Vector Borne Zoonotic Dis. 18, 356–363.

Lopes, E.G., Sevá, A.P., Ferreira, F., Nunes, C.M., Keid, L.B., Hiramoto, R.M., Ferreira, H. L., Oliveira, T.M.F.S., Ovallos, F.G., Galati, E.A.B., Villegas, T.J., Bortoletto, D.V., Valadas, S.Y.O.B., Soares, R.M., 2018. Vaccine effectiveness and use of collar impregnated with insecticide for reducing incidence of *Leishmania* infection in dogs in an endemic region for visceral leishmaniasis, in Brazil. Epidemiol. Infect. 146, 401–406.

Miró, G., Petersen, C., Cardoso, L., Bourdeau, P., Baneth, G., Solano-Gallego, L., Pennisi, M.G., Ferrer, L., Oliva, G., 2017. Novel areas for prevention and control of canine leishmaniosis. Trends Parasitol. 33, 718–730.

Moreno, J., Vouldoukis, I., Schreiber, P., Martin, V., McGahie, D., Gueguen, S., et al., 2014. Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish) produces a cell-mediated immune response which is still present 1 year later. Vet. Immunol. Immunopathol. 158, 199–207.

Oliva, G., Nieto, J., Foglia Manzillo, V., Cappiello, S., Fiorentino, E., Di Muccio, T., Scalone, A., Moreno, J., Chicharro, C., Carrillo, E., Butaud, T., Guegand, L., Martin,

V., Cuisinier, A.M., McGahie, D., Gueguen, S., Cañavate, C., Gradoni, L., . A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two *Leishmania infantum* transmission seasons. PLoS Negl. Trop. Dis. 8, e3213.

Otranto, D., Dantas-Torres, F., 2013. The prevention of canine leishmaniasis and its impact on public health. Trends Parasitol. 29, 339–345.

Otranto, D., Dantas-Torres, F., de Caprariis, D., Di Paola, G., Tarallo, V.D., Latrofa, M.S., Lia, R.P., Annoscia, G., Breitshwerdt, E.B., Cantacessi, C., Capelli, G., Stanneck, D., 2013. Prevention of canine leishmaniosis in a hyper-endemic area using a combination of 10% imidacloprid/4.5% flumethrin. PLoS One 8, e56374.

Palatnik-de-Sousa, C.B., Silva-Antunes, I., Morgado, A.A., Menz, I., Palatnik, M., Lavor, C., 2009. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 27, 3505–3512.

Paulin, S., Frénais, R., Thomas, E., Baldwin, P.M., 2018. Laboratory assessment of the anti-feeding effect for up to 12 months of a slow release deltamethrin collar (Scalibor®) against the sand fly *Phlebotomus perniciosus* in dogs. Parasit. Vectors 11, 529.

Quinnell, R.J., Courtenay, O., 2009. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 136, 1915–1934.

Regina-Silva, S., Feres, A.M., França-Silva, J.C., Dias, E.S., Michalsky, E.M., de Andrade, H.M., Coelho, E.A., Ribeiro, G.M., Fernandes, A.P., Machado-Coelho, G.L., 2016. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil. Vaccine 34, 2233–2239.

Rocha, I.C.M., Santos, L.H.M., Coura-Vital, W., da Cunha, G.M.R., Magalhães, F.D.C., da Silva, T.A.M., Morais, M.H.F., Oliveira, E., Reis, I.A., Carneiro, M., 2018. Effectiveness of the Brazilian Visceral Leishmaniasis Surveillance and Control Programme in reducing the prevalence and incidence of *Leishmania infantum* infection. Parasit. Vectors 11, 586.

Romero, G.A., Boelaert, M., 2010. Control of visceral leishmaniasis in Latin America-a systematic review. PLoS Negl. Trop. Dis. 4, e584.

Sevá, A.P., Ovallos, F.G., Amaku, M., Carrillo, E., Moreno, J., Galati, E.A., Lopes, E.G., Soares, R.M., Ferreira, F., 2016. Canine-based strategies for prevention and control of visceral leishmaniasis in Brazil. PLoS One 11, e0160058.

Shimozako, H.J., Wu, J., Massad, E., 2017. The preventive control of zoonotic visceral leishmaniasis: efficacy and economic evaluation. Comput. Math. Methods Med. 2017, 4797051.

Silva, R.A.E., Andrade, A.J., Quint, B.B., Raffoul, G.E.S., Werneck, G.L., Rangel, E.F., Romero, G.A.S., 2018. Effectiveness of dog collars impregnated with 4% deltamethrin in controlling visceral leishmaniasis in *Lutzomyia longipalpis* (Diptera: Psychodidade: Phlebotominae) populations. Mem. Inst. Oswaldo Cruz 113, e170377.

Solano-Gallego, L., Miró, G., Koutinas, A., Cardoso, L., Pennisi, M.G., Ferrer, L., Bourdeau, P., Oliva, G., Baneth, G., The LeishVet Group, 2011. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit. Vectors 4, 86.

Soutter, F., Solano-Gallego, L., Attipa, C., Gradoni, L., Fiorentino, E., Foglia Manzillo, V., Oliva, G., Tasker, S., Helps, C., Catchpole, B., 2019. An investigation of polymorphisms in innate and adaptive immune response genes in canine leishmaniosis. Vet. Parasitol. 269, 34–41.

Travi, B.L., Miró, G., 2018. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. Mem. Inst. Oswaldo Cruz 113, e180301.